Dr. Gail L. Daumit & Dr. Dan Siskind Named the 2026 Outstanding Clinical and Community Research Awardees
Dr. Gail Daumit
Professor of Medicine
Johns Hopkins University School of Medicine
Dr. Gail Daumit is a professor of medicine at the Johns Hopkins University School of Medicine. She holds a joint appointment in psychiatry and behavioral sciences. She also holds appointments in epidemiology, and health policy and management at the Johns Hopkins Bloomberg School of Public Health. Her areas of clinical expertise include clinical trials, epidemiology and health services research.
She earned her M.D. from Emory University School of Medicine. She completed her residency at Massachusetts General Hospital and performed a fellowship in internal medicine at Johns Hopkins, earning a M.H.S. in Epidemiology from the Johns Hopkins Bloomberg School of Public Health.
Dr. Daumit’s research is devoted to improving overall health and decreasing premature mortality for people with serious mental illnesses such as schizophrenia and bipolar disorder.
Her work has been recognized with several honors. In 2013, she received the Society of General Internal Medicine’s Best Published Research Paper of the Year Award for “The Randomized Trial of Achieving Healthy Lifestyles in Psychiatric Rehabilitation.” In 2014, the same research paper won the 2014 Trial of the Year Award from the Society for Clinical Trials. She is a member of the Society of General Internal Medicine.
In his curricular work, he has led the development and implementation of an Evidence-Based Medicine (EBM) based approach to enabling psychiatrists in training to ask, access, appraise and apply the best available scientific evidence to their practice and to audit the health of the populations they are responsible for.
Dr. Srihari also consults with academic and non-academic healthcare systems that seek to initiate or refine early intervention services for recent onset or 'first-episode' psychosis.
Dr. Dan Siskind
Clinical Psychiatrist
Prof Siskind trained as a psychiatrist in Australia and the United States. He works clinically as a psychiatrist in Brisbane, Australia with people with treatment refractory schizophrenia. His research interests include treatment refractory schizophrenia, clozapine and the physical health comorbidities associated with schizophrenia. He has over 300 publications and AU$60million in competitive research grants, with over AU $7 million as CIA.
A Message from Dan Siskind MBBS, MPH, PhD, FRANZCP, FAHMS
I am deeply honoured to receive the SIRS Outstanding Clinical and Community Research Award. To be recognised by colleagues within this remarkable international community is both humbling and profoundly meaningful.
My work has always been driven by an aim: to ensure that research in schizophrenia translates into tangible improvements in the lives of people living with psychosis. As a clinician working with individuals with treatment-resistant schizophrenia, I have seen how transformative effective treatments can be, and how system barriers can prevent access to them. Our team’s research has focused on improving safe access to clozapine, modernising monitoring frameworks, and reducing unnecessary treatment burden, while also addressing the cardiometabolic inequities that contribute to premature mortality.
This award reflects the efforts of an extraordinary team. I am deeply grateful to my colleagues, collaborators, trainees, and clinical team. The work on global consensus guidelines, clinical trials, and health policy reform has only been possible because of shared purpose, intellectual generosity, and sustained collaboration.
I am particularly thankful to people with lived experience of schizophrenia and their families, whose insights continually shape and strengthen our research.
